Esperion announced an agreement with Currax Pharmaceuticals that provides for all of Currax’s 72 sales representatives to co-promote NEXLETOL Tablets and NEXLIZET Tablets. This deal more than doubles the sales representatives for NEXLETOL and NEXLIZET and further demonstrates Esperion’s focus on driving persistent growth to the business.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on ESPR:
- Esperion Announces Co-Promotion Agreement With Currax Pharmaceuticals LLC
- Esperion to Participate in Needham 22nd Annual Virtual Healthcare Conference
- Esperion Announces Closing of $56.7 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
- Esperion prices $56.7M registered direct offering
- Biotech Alert: Searches spiking for these stocks today